Strategic Partnerships Stilla Technologies has recently partnered with Avantor, a global leader in life sciences and technology solutions, showcasing a strategic expansion into the United States. This partnership presents an opportunity for cross-selling and leveraging Avantor's existing customer base.
Innovative Product Line With the launch of 20 new digital PCR assays optimized for its Crystal Digital PCR™ platform, Stilla Technologies has enhanced its product line for detecting circulating tumor DNA. These new assays present a sales opportunity for oncology research facilities and diagnostic labs.
Financial Health Backed by a Series C financing of $26.5 million and boasting a revenue between $10-50 million, Stilla Technologies demonstrates financial stability and growth potential. This financial health makes them an attractive partner for institutions looking to invest in cutting-edge genetic testing technologies.
Award-Winning Technology The Red Dot Design Award-winning Nio™ family of products showcases the technological excellence of Stilla Technologies. This recognition can be leveraged in sales pitches to highlight the company's commitment to innovation and product quality, potentially attracting customers seeking top-tier solutions.
Industry Recognition Stilla Technologies' collaboration with Promega Corporation for a fully automated digital PCR analysis solution reflects industry recognition and endorsement. This association can be utilized in sales conversations to build credibility and trust with potential buyers in the biotechnology and genomic research sector.
1-888-653-2347 
support@leadiq.com 
